文献速递角膜与眼表疾病神经眼科

神经激肽-1受体阻断调控眼表疼痛

Modulating Ocular Surface Pain Through Neurokinin-1 Receptor Blockade.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2021-01-01

该研究在C57BL6/N野生型与TAC1敲除雄性小鼠上,用5 M NaCl刺激角膜并以甩眼试验量化眼表疼痛;结果显示TAC1敲除显著减少眼痛,局部应用NK1R拮抗剂福沙匹坦可有效减轻角膜痛觉,并降低泪液与三叉神经节中P物质含量及角膜白细胞浸润。

要点

  • TAC1敲除小鼠眼表疼痛显著降低(P < 0.001)。
  • 局部10或50 mg/mL福沙匹坦单次给药即显著减轻野生型小鼠眼痛(P < 0.001)。
  • 福沙匹坦或奥布卡因组泪液与三叉神经节SP含量、角膜TAC1 mRNA及白细胞浸润均降低(P < 0.05)。

核心结论

  • 局部应用NK1R拮抗剂福沙匹坦通过减少泪液和三叉神经节中SP释放及角膜白细胞浸润,有效降低眼表痛觉,重定位用于眼痛治疗有前景。

研究设计与样本

  • 使用8周龄C57BL6/N野生型与B6.Cg-Tac1tm1Bbm/J(TAC1-KO)雄性小鼠。
  • 角膜局部给予5 M NaCl后用甩眼试验量化眼表疼痛。
  • 检测泪液与三叉神经节SP含量、角膜TAC1 mRNA,并免疫染色β3-tubulin、NK1R与CD45。

主要发现

  • TAC1-KO小鼠眼痛显著减少(P < 0.001)。
  • 野生型小鼠局部单次10或50 mg/mL福沙匹坦较溶媒显著减轻眼痛(P < 0.001)。
  • 2 mg/mL福沙匹坦仅在每日6次、连续10天给药时产生角膜镇痛(P < 0.05)。
  • 双氯芬酸或奥布卡因较溶媒或福沙匹坦减轻角膜痛觉(P < 0.05)。
  • 福沙匹坦或奥布卡因组泪液与三叉神经节SP含量降低、角膜TAC1 mRNA减少、角膜白细胞浸润减少(均P < 0.05)。

关键数值与推荐

  • 福沙匹坦局部浓度为2、10、50 mg/mL;奥布卡因为4 mg/mL;双氯芬酸为0.1%。
  • 2 mg/mL福沙匹坦需每日6次、连续10天方见镇痛效果(P < 0.05)。

临床怎么用

  • 提示NK1R阻断(福沙匹坦局部给药)可能作为眼表疼痛的候选治疗方向。
  • 临床决策仍需人体研究验证剂量、频次与安全性,不能直接照搬小鼠数据。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to test the role of substance P (SP) and its receptor neurokinin 1 (NK1R) on ocular surface pain. METHODS: Eight-week-old C57BL6/N (wild type [WT]) and B6.Cg-Tac1tm1Bbm/J (TAC1-KO) male mice were used. 5 M NaCl was topically applied on the cornea, followed by topical fosaprepitant 2, 10, and 50 mg/mL; 4 mg/mL oxybuprocaine chloride, or 0.1% diclofenac. Th eye wiping test was used to quantify ocular surface pain. SP content was quantified in the tear fluid and trigeminal ganglia (TG), and TAC1 mRNA was assessed in the cornea. Corneas were immunostained for β3-tubulin and NK1R, or CD45, to quantify leukocyte infiltration. RESULTS: TAC1-KO mice displayed a significant reduction of ocular pain (P < 0.001). Similarly, a single dose of 10 or 50 mg/mL fosaprepitant applied topically to WT mice reduced ocular pain as compared to vehicle (P < 0.001). Fosaprepitant 2 mg/mL, instead, induced corneal analgesia only when it was administered for 10 days, 6 times/day (P < 0.05). Diclofenac or oxybuprocaine reduced corneal nociception when compared to vehicle or fosaprepitant (P < 0.05). Fosaprepitant or oxybuprocaine groups showed lower SP content in tear secretions and TG (P < 0.05), and reduction in TAC1 mRNA (P < 0.05), and leukocyte infiltration (P < 0.05) in the cornea. Colocalization of NK1R and β3-tubulin was detected in mouse corneas. CONCLUSIONS: Topical administration of the NK1R antagonist fosaprepitant effectively reduces ocular surface nociception by decreasing SP release in the tear fluid and TG, and corneal leukocyte infiltration. Fosaprepitant repurposing shows promise for the treatment of ocular pain.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lasagni Vitar RM, Barbariga M, Fonteyne P, et al. Modulating Ocular Surface Pain Through Neurokinin-1 Receptor Blockade. Invest Ophthalmol Vis Sci. 2021. PMID: 33729475. doi:10.1167/iovs.62.3.26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。